Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Published:2015-10-21 Issue:3 Volume:30 Page:633-639
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kaufman G P,Gertz M A,Dispenzieri A,Lacy M Q,Buadi F K,Dingli D,Hayman S R,Kapoor P,Lust J A,Russell S,Go R S,Hwa Y L,Kyle R A,Rajkumar S V,Kumar S K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015287.pdf

Reference23 articles.

1. Boccadoro M, Cavallo F, Gay FM, Di Raimondo F, Nagler A, Montefusco V et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 2013; Suppl (ASCO abstracts): abstract 8509.

2. Palumbo A, Gay F, Spencer A, Di Raimondo F, Zdenek A, Larocca A et al. A phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood 2013; 122 (ASH abstracts): 763.

3. Moreau P, Attal M . All transplantation-eligible patients with myeloma should receive ASCT in first response. Hematology 2014; 2014: 250–254.

4. Rchardson PG, Laubach JP, Munshi NC, Anderson KC . Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology 2014; 2014: 255–261.

5. Chng WJ, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269–277.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma;Cancers;2023-12-13

2. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China;Hematology;2023-11-29

3. Analysis of the epidemiological characteristics of multiple myeloma and clinical factors affecting the course of the disease;Medical and Biological Problems of Life Activity;2023-05-22

4. Multiple myeloma with t(11;14): impact of novel agents on outcome;Blood Cancer Journal;2023-03-20

5. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era;Hematology;2023-01-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3